


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY DISCLOSURE
2024 THIRD QUARTER UPDATE

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby provides a voluntary disclosure on selected unaudited operational and financial information of the Group for the three months ended 30 September 2024.

In the third quarter of 2024, with the overall growth and recovery in the pharmaceutical industry, the Company timely grasped the opportunity and accelerated the progress of research and development, manufacturing, and sales, and its innovative products demonstrated a continuous sales ramp-up, thus driving the rapid growth in the Group’s results for the third quarter.

In the third quarter of 2024, the Group recorded the revenue¹ (unaudited) of approximately RMB5.47 billion, representing an increase of approximately 14.3% compared with the same period last year; the profit attributable to the owners of the parent (unaudited) amounted to approximately RMB1.15 billion, representing an increase of approximately 123.4% over the same period last year; and the adjusted non-HKFRS profit attributable to the owners of the parent² (unaudited) amounted to approximately RMB0.60 billion, representing an increase of approximately 58.0% over the same period last year.

During the first three quarters of 2024, the Group recorded the revenue¹ (unaudited) of approximately RMB21.35 billion, representing an increase of approximately 11.9% over the same period last year; the profit attributable to the owners of the parent (unaudited) of approximately RMB4.17 billion, representing an increase of approximately 134.9% over the same period last year; and the adjusted non-HKFRS profit attributable to the owners of the parent² (unaudited) amounted to approximately RMB2.14 billion, representing an increase of approximately 23.7% over the same period last year.

The Group will continue to focus on innovation as well as research and development in the four major therapeutic areas, namely oncology, liver diseases, respiratory system and surgery/analgesia, while accelerating the marketing launch of its products. The Group has entered an intensive harvest period for its innovative products, and the Group is confident in its continuous growth in the future.

Notes:

1. The revenue from discontinued operations has been excluded for 2024 and 2023.
2. For the definition of the adjusted non-HKFRS profit attributable to the owners of the parent, please refer to the 2024 interim report of the Company. The adjusted non-HKFRS profit attributable to the owners of the parent excluded the impacts from certain non-cash items and one-off profits or losses, including the exclusion of the profit attributable to the owners of the parent related to discontinued operations for the first half of 2024 of approximately RMB1.61 billion.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 30 October 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.